Avaliação da eficiência das terapias aplicadas na Síndrome da Ardência Bucal: revisão sistemática e metanálise

Resumo (EN)

The Burning Mouth Syndrome (BMS) is a chronical and complex disorder of orofacial sensation, characterized by the burning of the buccal mucosa of absent local or systemic pathological clinical signs and of absent laboratorial findings. It is an incapacitating clinical condition. The BMS physiopathology is not well-understood and it probably involves interactions among local, systemic, and/or psychogenic factors. Recent reports suggest the existence of a neuropathic mechanism. Several therapeutic possibilities for BMS are being applied, such as: paroxetine, clonazepam, gabapentin, alpha lipoic acid (ALA), capsaicin, benzydamine, trazodone), topical medication (clonazepam, lidocaine, capsaicin, artificial saliva) and nonpharmacological therapies (psychotherapy, cognitive approach, yoga, meditation, relaxation therapy, acupuncture, tongue protector, laser therapy, eletroconvulsotherapy). The objective of this systematic review (SR) was to verify the efficiency of therapies used in the idiopathic BMS treatment. A wide data research was carried out in different databases: EMBASE, MEDLINE, PubMed, BIREWME (BVS), LILACS, IBECS, BBO, and SIbiUSP, after a systematic search criterion and eligibility of the studies, which resulted in 21 randomized clinical trials (RCTs) with low risk of bias. Out of the qualitative synthesis, seven studies of compared placebo were considered eligible for the quantitative analysis (meta analysis). It was concluded that from the meta-analysis (WMD: -1.82.95% CI: -3.09, -0.55, p = 0.0051), the use of a therapy is significantly more efficient in patients with BMS than placebo. More standardized studies within each within a same therapy and placebo compared RCTs are required.